Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Vection Technologies

    MCap

    AUD28m

    Last close

    AUD0.03

    ▲ 0.01 (50.00%)

    Biodexa Pharmaceuticals

    MCap

    USD3m

    Last close

    USD5.11

    ▲ 1.61 (46.00%)

    Pharnext

    MCap

    EUR1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Ultimovacs (OSE: ULTI)

Currency in NOK

Last close As at 06/12/2023

NOK110.60

▲ 3.40 (3.17%)

Market capitalisation

NOK3,805m

Ultimovacs is developing novel immunotherapies against cancer. Its lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT), which is expressed in c 85% of all cancer types. UV1 therefore has a broad potential in a variety of different settings and combinations.

Novel drug projects in oncology comprise the lion’s share of total R&D investments in the industry. Around 85% of all cancer types express high levels of hTERT, which means that UV1 has a broad potential in a variety of different settings, including combinations with other cancer treatments.

Latest Insights

View More

Healthcare | Update

Ultimovacs — Staying alive with UV1 in NIPU and INTIUM

Healthcare | Flash note

Ultimovacs — Line of sight on INITIUM top-line readout

Healthcare | research

Ultimovacs — Overall survival is the name of the NIPU PII game

Healthcare | Flash note

Ultimovacs — Two for two in melanoma Phase I trial
Ultimovacs_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Key Management

  • Carlos de Sousa

    CEO

  • Gustav Gaudernack

    CSO

  • Hans Vassgård Eid

    CFO

  • Jens Bjørheim

    CMO

  • Ton Berkien

    CBO

Balance Sheet

Forecast net cash (NOKm)

346.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 10.9 55.8 (3.5)
Relative 11.1 56.1 (4.0)
52 week high/low NOK147.8/NOK68.3

Financials

Ultimovacs is a biotechnology company focused on developing a next generation cancer vaccine with virtually universal potential. Lead asset UV1 activates the immune system to recognise cancer cells that express hTERT, which is present in c 85–90% of all cancer types. For this reason, UV1 has broad potential in a variety of cancers and in combination with other treatments. The company’s R&D strategy is to combine UV1 with checkpoint inhibitors due to an expected treatment synergy. The broad R&D programme includes five Phase II trials in different solid tumours, which will enrol more than 600 patients in total. Readouts are expected over 2023–25. The most near-term catalyst for the share price is top-line readouts from the Phase II INITIUM study in malignant melanoma, which are on-track to be shared in March or April 2024.

Y/E Dec Revenue (NOKm) EBITDA (NOKm) PBT (NOKm) EPS (fd) (öre) P/E (x) P/CF (x)
2021A 0.0 (161.1) (164.7) (508.83) N/A N/A
2022A 0.0 (181.0) (167.8) (489.06) N/A N/A
2023E 0.0 (211.1) (191.5) (556.62) N/A N/A
2024E 0.0 (232.3) (235.9) (685.68) N/A N/A

Research

Ultimovacs_resized

Flash note

Healthcare

Ultimovacs — Line of sight on INITIUM top-line readout

research

Healthcare

Ultimovacs — Overall survival is the name of the NIPU PII game
Ultimovacs_resized

Healthcare

Update

Ultimovacs — Staying alive with UV1 in NIPU and INTIUM

Ultimovacs_resized
View All

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

thematic

Healthcare

Machine learning in drug development
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free